The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The FDA has determined that the nationwide shortage of semaglutide injection, used for both diabetes and weight loss, is resolved after more than two years of limited availability due to high demand.

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

A new study has found that semaglutide — the active substance in Ozempic and Wegovy — may help reduce alcohol cravings in people with AUD. Despite the availability of treatment options ...

The Zappy chat was ultimately how many customers first learned that Ousia Pharmacy — one of several pharmacies that supplied Zappy with compounded obesity drugs — didn't have a required ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Wegovy and Ozempic have the same active ingredient, semaglutide. “Technically, they are exactly the same,” Dr. Maria Daniela Hurtado Andrade, an endocrinologist at the Mayo Clinic’s ...

The mouse on the right with four times the normal muscle mass is placed with a normal mouse. Handout via REUTERS About a dozen drugmakers are developing new weight-loss treatments aimed at ...

CNET’s expert staff reviews and rates dozens of new products and services each month, building on more than a quarter century of expertise.